Home › Agenus Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation
 

Keywords :   


Agenus Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation

2014-07-02 10:39:34| drugdiscoveryonline Home Page

Agenus Inc. an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, recently announced promising Phase 2 results for HerpV, a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 (HSV-2)

Tags: shows significant generated reduction

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Atlantic Tropical Weather Outlook
28.09Eastern North Pacific Tropical Weather Outlook
27.09Washington Corner | September 2024
27.09Hurricane Isaac Graphics
27.09Remnants of John Graphics
27.09Remnants of John Forecast Discussion Number 20
27.09Remnants of John Wind Speed Probabilities Number 20
27.09Remnants of John Public Advisory Number 20
More »